TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aptose Biosciences ( (TSE:APS) ) has provided an update.
On November 18, 2025, Aptose Biosciences Inc. entered into a definitive arrangement agreement with Hanmi Pharmaceuticals Co. Ltd. and its subsidiary, under which Hanmi will acquire all outstanding common shares of Aptose not already owned by Hanmi. The acquisition offers a 28% premium over Aptose’s 30-day VWAP on the TSX. The transaction is subject to customary closing conditions, including court and shareholder approval. Post-transaction, Aptose will be delisted from stock exchanges, and no longer subject to Canadian securities reporting requirements. The board of Aptose unanimously supports the arrangement, deeming it in the best interest of the company.
The most recent analyst rating on (TSE:APS) stock is a Hold with a C$2.41 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.
Spark’s Take on TSE:APS Stock
According to Spark, TipRanks’ AI Analyst, TSE:APS is a Underperform.
Aptose Biosciences faces significant financial distress with no revenue generation and substantial losses. The negative technical indicators and valuation metrics further highlight the stock’s weak position. However, recent corporate events provide a glimmer of hope with potential advancements in AML treatment and strategic partnerships, slightly mitigating the overall risks. The stock remains risky, requiring cautious optimism for future developments.
To see Spark’s full report on TSE:APS stock, click here.
More about Aptose Biosciences
Aptose Biosciences Inc. operates in the biotechnology industry, focusing on developing targeted therapies for cancer treatment. The company is known for its innovative approach to addressing unmet medical needs in oncology.
Average Trading Volume: 4,026
Technical Sentiment Signal: Sell
Current Market Cap: C$5.85M
Find detailed analytics on APS stock on TipRanks’ Stock Analysis page.